Aethlon Medical Inc
aethlonmedical.comWhat Do They Do?
Develops the Hemopurifier, an investigational device intended to remove enveloped viruses and disease-related particles from blood plasma for potential use in cancer, infectious diseases and organ transplantation.
10-K for FY2026, filed Jun 10, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Aug 13, 2026
−$1.5MView ↗
- ▼ −12% (Loss)
- vs −$1.8M in Q1 FY2026
-
Sep 17, 2026
Agreed to merge with North Immunology
North Immunology stockholders are expected to own approximately 95.25% of the combined company, which is expected to operate as North Immunology.
Sources
8-K, filed Sep 17, 2026
Under the terms of the merger agreement, as of the closing of the proposed merger, the pre-merger Aethlon stockholders are expected to own…View ↗
Broader research applications
The older report framed the Hemopurifier around cancer and life-threatening viral infections; the latest also describes research into other extracellular-vesicle-related disease states, including Long COVID.
10-K for FY2023, filed Jun 28, 2023 10-K for FY2026, filed Jun 10, 2026Aethlon Medical, Inc., or Aethlon, the Company, we or us, is a medical therapeutic company focused on developing products to treat cancer…View ↗
Who Do They Compete With?
Competes with ExThera Medical
10-K for FY2026, filed Jun 10, 2026The industry for treating infectious disease and cancer is extremely competitive, and companies developing new treatment procedures face…View ↗
Loading...
